Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572169 · ClinicalTrials.gov registry record · Phase 3
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
A Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
- Active
- Registry status
- Phase 3
- Development phase
- 177
- Enrollment target
- 1
- Study location
NCT00572169: Active Phase 3 study of Multiple Myeloma, sponsored by University of Arkansas.
NCT00572169 is a Phase 3 study of Multiple Myeloma that is active but no longer recruiting, run by University of Arkansas. The registered enrollment target is 177 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572169, a Phase 3 study of Multiple Myeloma, is active but no longer recruiting, sponsored by University of Arkansas.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 177 participants
- Enrollment target
- 1
- Study location
Study Summary
With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma affect the outcome of drug therapy used in this disease."
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Dexamethasone
- DRUG Thalidomide
- DRUG Velcade
- DRUG Adriamycin
Study Locations (1)
Arkansas
- University of Arkansas for Medical Sciences/Myeloma Institute - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 177 participants |
| Start Date | 2006-11 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What the registry record for NCT00572169 still lists
NCT00572169 is an interventional study that assigns participants to a tested intervention. The registered 177 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT00572169 reports a single indexed study location in Arkansas.
Frequently Asked Questions
What is clinical trial NCT00572169 about?
NCT00572169 is a clinical study titled "UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy". With this study - Total Therapy IIIB - researchers are extending the findings of Total Therapy III based what they have learned from the first two studies (Total Therapy I and II), with new research strategies designed to explore why chromosome abnormalities found in persons with multiple myeloma af...
What is the current status of trial NCT00572169?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 177 participants. The study started on 2006-11. Estimated completion is 2027-08.
What conditions does trial NCT00572169 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00572169?
The interventions under investigation include: Cisplatin (DRUG), Dexamethasone (DRUG), Thalidomide (DRUG), Velcade (DRUG), Adriamycin (DRUG).
Who is sponsoring clinical trial NCT00572169?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00572169 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00572169's enrollment target sits among peer trials
177 122nd of 438 higher than 316 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491551 · 177 participants · NA
Alcohol-ROC-Training
- NCT06108050 · 177 participants · Phase 1
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
- NCT06575712 · 177 participants · NA
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
- NCT06674980 · 177 participants · NA
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia